168 related articles for article (PubMed ID: 14741215)
1. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes.
Schon O; Friedler A; Freund S; Fersht AR
J Mol Biol; 2004 Feb; 336(1):197-202. PubMed ID: 14741215
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of the interaction between MDM2 and p53.
Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
[TBL] [Abstract][Full Text] [Related]
3. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
[TBL] [Abstract][Full Text] [Related]
4. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
6. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
[TBL] [Abstract][Full Text] [Related]
7. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation.
McCoy MA; Gesell JJ; Senior MM; Wyss DF
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1645-8. PubMed ID: 12552135
[TBL] [Abstract][Full Text] [Related]
8. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
[TBL] [Abstract][Full Text] [Related]
10. Autoinhibition of MDMX by intramolecular p53 mimicry.
Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
[TBL] [Abstract][Full Text] [Related]
11. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
Zondlo SC; Lee AE; Zondlo NJ
Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
[TBL] [Abstract][Full Text] [Related]
12. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
[TBL] [Abstract][Full Text] [Related]
13. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA.
Burch LR; Midgley CA; Currie RA; Lane DP; Hupp TR
FEBS Lett; 2000 Apr; 472(1):93-8. PubMed ID: 10781812
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
Liu Z; Olejniczak ET; Fesik SW
Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.
García-Echeverría C; Chène P; Blommers MJ; Furet P
J Med Chem; 2000 Aug; 43(17):3205-8. PubMed ID: 10966738
[No Abstract] [Full Text] [Related]
16. Design of a novel MDM2 binding peptide based on the p53 family.
Madhumalar A; Lee HJ; Brown CJ; Lane D; Verma C
Cell Cycle; 2009 Sep; 8(17):2828-36. PubMed ID: 19713735
[TBL] [Abstract][Full Text] [Related]
17. p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53.
Chen L; Yin H; Farooqi B; Sebti S; Hamilton AD; Chen J
Mol Cancer Ther; 2005 Jun; 4(6):1019-25. PubMed ID: 15956260
[TBL] [Abstract][Full Text] [Related]
18. Dual-site regulation of MDM2 E3-ubiquitin ligase activity.
Wallace M; Worrall E; Pettersson S; Hupp TR; Ball KL
Mol Cell; 2006 Jul; 23(2):251-63. PubMed ID: 16857591
[TBL] [Abstract][Full Text] [Related]
19. A genetic approach to mapping the p53 binding site in the MDM2 protein.
Freedman DA; Epstein CB; Roth JC; Levine AJ
Mol Med; 1997 Apr; 3(4):248-59. PubMed ID: 9131587
[TBL] [Abstract][Full Text] [Related]
20. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
Shin JS; Ha JH; Chi SW
Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]